
AMGEN/X
Jun 25, 2025, 16:24
Results From Amgen’s Phase 2 Obesity Study of Monthly Maritide Presented at the American Diabetes Association 85th Scientific Sessions
Amgen shared a post on X:
“Results from Amgen’s Phase 2 obesity study being presented during an expert-led symposium at the American Diabetes Association 85th Scientific Sessions.
The data evaluated MariTide in people living with obesity, with and without Type 2 diabetes.
Proceed to the video attached to the post.
More posts featuring AMGEN.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 9, 2025, 23:47
Jul 9, 2025, 23:31
Jul 9, 2025, 23:14
Jul 9, 2025, 23:06
Jul 9, 2025, 22:41